Key Points
- EVP Marc Nash sold 5,375 shares on Jan. 20 at an average price of $5.12 for $27,520, leaving him with 42,785 shares and representing an 11.16% reduction in his ownership.
- Other senior insiders — including CEO Leslie Trigg and General Counsel John L. Brottem — also sold large blocks on Jan. 20–21, indicating concentrated insider selling across management.
- Outset Medical (OM) trades near $5.20 with a market cap of about $94.4M, a 52-week range of $3.10–$21.98, 50-day/200-day SMAs of $4.33/$11.03, and mixed analyst coverage giving a consensus "Moderate Buy" and $10.67 price target.
Outset Medical, Inc. (NASDAQ:OM - Get Free Report) CEO Leslie Trigg sold 2,120 shares of the business's stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $5.05, for a total transaction of $10,706.00. Following the transaction, the chief executive officer owned 105,703 shares in the company, valued at $533,800.15. This trade represents a 1.97% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Leslie Trigg also recently made the following trade(s):
- On Tuesday, January 20th, Leslie Trigg sold 11,794 shares of Outset Medical stock. The stock was sold at an average price of $5.12, for a total transaction of $60,385.28.
- On Wednesday, January 7th, Leslie Trigg sold 1,795 shares of Outset Medical stock. The shares were sold at an average price of $4.27, for a total value of $7,664.65.
- On Monday, November 17th, Leslie Trigg sold 916 shares of Outset Medical stock. The shares were sold at an average price of $4.60, for a total transaction of $4,213.60.
Outset Medical Trading Up 3.0%
OM opened at $5.20 on Thursday. Outset Medical, Inc. has a 52 week low of $3.10 and a 52 week high of $21.98. The company has a market capitalization of $94.38 million, a P/E ratio of -0.40 and a beta of 2.07. The stock's fifty day moving average is $4.33 and its two-hundred day moving average is $11.03. The company has a quick ratio of 5.77, a current ratio of 7.09 and a debt-to-equity ratio of 0.69.
Analyst Ratings Changes
A number of research analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Outset Medical in a research report on Monday, December 29th. Stifel Nicolaus cut their price target on shares of Outset Medical from $14.00 to $8.00 and set a "buy" rating on the stock in a report on Wednesday, January 7th. Royal Bank Of Canada reiterated a "sector perform" rating and set a $7.00 price objective on shares of Outset Medical in a report on Wednesday, December 17th. BTIG Research restated a "buy" rating and set a $17.00 target price on shares of Outset Medical in a research note on Tuesday, December 16th. Finally, Wall Street Zen lowered Outset Medical from a "hold" rating to a "sell" rating in a research report on Saturday, January 10th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Outset Medical presently has an average rating of "Moderate Buy" and an average price target of $10.67.
View Our Latest Analysis on OM
Outset Medical News Summary
Here are the key news stories impacting Outset Medical this week:
- Negative Sentiment: CEO Leslie Trigg sold a total of 13,914 shares across Jan. 20–21 (two filings), reducing her stake; the bulk was sold at ~ $5.12 per share. These disclosures can be viewed on the SEC filing. CEO Filings
- Negative Sentiment: General Counsel John L. Brottem sold a total of 10,494 shares across Jan. 20–21 at ~ $5.01–$5.12 per share, cutting his position materially (one filing shows a ~20% reduction). See the SEC disclosure. GC Filings
- Negative Sentiment: EVP Marc Nash sold 6,355 shares across Jan. 20–21 at ~ $4.98–$5.12 per share, reducing his holding by double-digit percentages in one filing. See the SEC filing for details. EVP Filings
Hedge Funds Weigh In On Outset Medical
Several hedge funds have recently made changes to their positions in OM. Legal & General Group Plc purchased a new stake in Outset Medical during the 2nd quarter valued at about $34,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Outset Medical during the second quarter worth about $35,000. BNP Paribas Financial Markets boosted its position in Outset Medical by 7,013.8% in the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company's stock valued at $40,000 after buying an additional 2,034 shares during the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new position in Outset Medical during the 2nd quarter worth approximately $78,000. Finally, New York State Common Retirement Fund purchased a new position in Outset Medical during the 2nd quarter worth approximately $108,000.
About Outset Medical
(
Get Free Report)
Outset Medical is a medical technology company specializing in innovations for renal care. The company's flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.
Tablo's modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
